influenza
viru
respiratori
pathogen
respons
death
annual
worldwid
vaccin
costeffect
way
prevent
control
influenza
outbreak
current
licens
inactiv
influenza
vaccin
iiv
includ
hemagglutinin
ha
viral
surfac
protein
induc
strainspecif
antibodi
respons
protect
antigen
match
close
relat
virus
howev
due
high
mutat
rate
ha
yearli
updat
season
vaccin
requir
match
circul
virus
addit
season
vaccin
effect
newli
emerg
influenza
virus
pandem
outbreak
reason
univers
influenza
vaccin
could
offer
broadrang
protect
subtyp
influenza
viru
focu
research
effort
last
two
decad
addit
adjuv
increas
breadth
immun
elicit
season
pandem
influenza
vaccin
suffici
overcom
limit
season
vaccin
strain
chang
therefor
sever
new
approach
taken
toward
develop
univers
influenza
vaccin
includ
induct
heterosubtyp
immun
direct
intern
antigen
conserv
protein
nucleoprotein
np
matrix
protein
antigen
highli
conserv
share
homolog
amino
acid
level
among
differ
influenza
strain
addit
tcell
respons
np
antigen
associ
earli
viru
clearanc
reduc
diseas
sever
absenc
neutral
antibodi
np
elicit
crossreact
cytotox
lymphocyt
use
acceler
viral
clearanc
addit
nonneutr
antibodi
might
antivir
activ
previou
preclin
studi
demonstr
differ
type
vaccin
contain
np
alon
combin
influenza
antigen
includ
plasmid
dna
doublestrand
ds
dna
viral
vector
peptid
adjuv
protein
subunit
protect
homolog
also
heterosubtyp
influenza
challeng
vaccin
live
attenu
influenza
vaccin
laiv
iiv
shown
induc
tcell
respons
intern
influenza
antigen
may
correl
better
heterosubtyp
protect
observ
laiv
iiv
children
howev
efficaci
laiv
affect
age
vaccine
extent
antigen
similar
vaccin
circul
strain
nucleic
acidbas
vaccin
base
mrna
may
provid
potent
altern
previous
mention
approach
preclin
studi
prophylact
therapeut
mrna
vaccin
demonstr
abil
elicit
function
antibodi
tcell
respons
mrna
vaccin
preclud
safeti
concern
dna
integr
host
genom
directli
translat
host
cell
cytoplasm
circumv
hurdl
present
nuclear
transport
moreov
simpl
cellfre
vitro
synthesi
rna
avoid
manufactur
complic
associ
viral
vector
two
differ
form
rnabas
vaccin
current
develop
influenza
convent
nonamplifi
mrna
selfamplifi
mrna
molecul
nonvir
deliveri
selfamplifi
mrna
technolog
deriv
modifi
alphaviru
singlestrand
ss
rna
genom
elicit
potent
broadbas
immun
respons
due
antigen
express
host
cell
intrins
innat
immun
stimul
capabl
technolog
alreadi
proven
success
variou
diseas
target
like
hiv
rsv
cmv
influenza
anim
model
includ
mice
cotton
rat
ferret
nonhuman
primat
present
studi
toward
develop
broadspectrum
influenza
vaccin
evalu
mice
immunogen
efficaci
sam
vector
encod
np
antigen
separ
combin
use
lipid
nanoparticl
lnp
synthet
nonvir
deliveri
system
show
sam
vector
immunogen
induc
antigenspecif
antibodi
tcell
respons
protect
mice
homolog
heterosubtyp
influenza
viru
challeng
rna
prepar
previous
report
briefli
dna
plasmid
encod
fulllength
np
sam
np
sam
influenza
viru
apuerto
amplifi
escherichia
coli
purifi
use
qiagen
plasmid
maxi
kit
qiagen
dna
linear
immedi
follow
end
selfamplifi
rna
sequenc
digest
pmei
linear
dna
templat
transcrib
rna
use
megascript
kit
life
technolog
purifi
licl
precipit
rna
cap
use
cap
system
cell
script
purifi
licl
precipit
bicistron
vector
sam
np
gene
clone
downstream
two
distinct
subgenom
promot
order
obtain
two
separ
entir
protein
babi
hamster
kidney
cell
bhk
atcc
cultur
dulbecco
modifi
eagl
medium
gibco
carlsbad
ca
contain
fetal
bovin
serum
hyclon
use
confluenc
time
transfect
determin
effici
rna
selfamplif
bhk
cell
electropor
puls
ng
rna
incub
h
cell
collect
stain
livedead
aqua
invitrogen
fix
permeabil
cytofixcytoperm
bd
bioscienc
stain
apcconjug
antidoubl
strand
ds
rna
antibodi
monoclon
mab
mous
kappa
chain
bioclass
antidsrna
conjug
use
zenon
allophycocianin
label
kit
invitrogen
frequenc
dsrna
cell
measur
flow
cytometri
fac
canto
ii
flow
cytomet
bd
bioscienc
determin
effici
protein
express
bhk
cell
transfect
sam
construct
lipofectamin
invitrogen
accord
manufactur
instruct
bhk
cell
collect
h
transfect
stain
livedead
aqua
fix
permeabil
cytofixcytoperm
flow
cytometri
analysi
np
express
assess
use
fitcconjug
antinp
monoclon
thermo
fisher
scientif
pierc
wherea
express
detect
use
monoclon
abd
serotec
apcconjug
secondari
antibodi
invitrogen
western
blot
analys
transfect
bhk
cell
lyse
whole
cell
lysat
cell
subject
sdspage
blot
pvdf
membran
np
detect
antinp
purifi
hybridoma
atcc
clone
detect
monoclon
antibodi
abd
serotec
follow
horseradish
peroxidaseconjug
goat
antimous
igg
secondari
antibodi
perkinelm
protein
band
visual
chemiluminesc
follow
manufactur
instruct
pierc
protein
research
product
rockford
il
rna
formul
lnp
previous
describ
dilut
desir
rna
concentr
pb
sam
np
sam
formul
equal
amount
sam
np
sam
rna
mix
prior
complexion
lnp
case
final
formul
vaccin
dilut
maintain
amount
rna
express
np
singl
vector
formul
character
particl
size
rna
concentr
encapsul
effici
antigen
express
transfect
cell
mouseadapt
influenza
viru
wack
franci
crick
institut
london
influenza
viru
ahong
bei
resourc
niaid
nih
reassort
influenza
viru
cal
novarti
vaccin
srl
siena
grown
allanto
caviti
embryon
chicken
egg
virus
titrat
madindarbi
canin
kidney
mdck
cell
quantifi
tissu
cultur
infecti
dose
yield
infect
store
clinic
score
system
use
defin
mous
lethal
dose
virus
clinic
score
rang
symptom
moribund
ascrib
mous
score
defin
human
endpoint
mous
immunogen
efficaci
studi
conduct
gsk
vaccin
anim
research
center
complianc
arriv
guidelin
current
italian
legisl
legisl
decre
gsk
anim
welfar
polici
standard
balbc
mice
charl
river
laboratori
calco
itali
age
week
immun
intramuscularli
im
day
quadricep
muscl
hind
leg
vaccin
formul
per
leg
sam
np
sam
sam
sam
np
sam
parallel
group
mice
infect
intranas
per
nostril
low
dose
influenza
virus
control
miivsam
coadministr
studi
miiv
influenza
strain
differ
sam
vaccin
coformul
prior
inject
administ
syring
np
igg
titer
determin
individu
sera
collect
week
first
week
second
immun
maxisorp
plate
nunc
coat
overnight
np
protein
sinobiolog
block
smartblock
candor
h
serum
sampl
standard
serum
serial
dilut
pb
bsa
tween
transfer
coat
block
plate
incub
h
detect
antigenspecif
igg
antibodi
plate
incub
alkalin
phosphataseconjug
goat
antimous
igg
sigma
min
pnitrophenyl
phosphat
disodium
substrat
ad
reaction
stop
ad
edta
ph
absorb
measur
spectramax
reader
molecular
devic
nm
titer
normal
respect
refer
serum
assay
parallel
indic
elisa
unitsml
euml
heatinactiv
pool
sera
serial
dilut
minim
essenti
medium
gibco
penicillin
streptomycin
glutamin
solut
life
technolog
trypsin
incub
h
influenza
cal
viru
viru
equival
work
dilut
elisabas
microneutr
assay
confirm
viru
back
titrat
includ
experiment
plate
data
shown
first
dilut
test
sampl
incub
h
mdck
cell
plate
plate
cellswel
cell
wash
pb
fix
fixat
buffer
bd
cytofix
permeabil
solut
pb
bsa
tween
plate
incub
fitcconjug
monoclon
antibodi
np
antigen
oxoid
h
wash
incub
horseradish
peroxidaseconjug
antifitc
polyclon
antibodi
roch
ophenylenediamin
dihydrochlorid
sigma
use
substrat
absorb
record
nm
use
spectramax
reader
molecular
devic
inhibit
infect
determin
fit
curv
softmaxpro
correspond
titer
repres
reciproc
dilut
titer
assign
sera
gave
neg
result
first
dilut
test
assess
antigenspecif
tcell
respons
singlecel
suspens
prepar
spleen
lung
cell
plate
mab
final
concentr
pharmingen
fitc
bd
bioscienc
cell
stimul
h
np
peptid
tyqrtralv
jpt
recombin
np
protein
sino
biolog
inc
peptid
pool
librari
consist
peptid
overlap
amino
acid
depart
biochemistri
univers
lausann
switzerland
tcell
respons
peptid
pool
jpt
peptid
pool
depart
biochemistri
univers
lausann
switzerland
use
vitro
stimul
number
cell
incub
alon
posit
neg
control
respect
brefeldin
sigma
ad
last
h
flow
cytometri
analys
cell
stain
livedead
near
infrar
invitrogen
bd
pharmingen
apc
ebiosci
fix
permeabil
cytofixcytoperm
bd
bioscienc
incub
fc
block
bd
bioscienc
cell
stain
brilliant
violet
brilliant
violet
bd
pharmingen
pe
pe
ebiosci
pe
texa
red
invitrogen
sampl
acquir
lrsii
special
order
bd
bioscienc
analyz
use
flowjo
softwar
version
treestar
cell
identifi
previous
describ
frequenc
antigenspecif
cell
calcul
subtract
background
measur
correspond
neg
control
cytokin
balbc
mice
immun
im
twice
week
apart
sam
np
sam
np
sam
sam
prepar
target
cell
splenocyt
mice
split
two
popul
one
popul
puls
h
peptid
tyqrtralv
wash
label
cfse
cfse
cell
popul
puls
unrel
peptid
amqmlketi
label
cmtmr
cmtmr
cell
equal
number
cell
total
splenocyt
two
differ
peptidepuls
label
popul
mix
inject
iv
immun
mice
day
second
immun
mice
sacrif
h
later
splenocyt
analyz
lrsii
special
order
bd
bioscienc
determin
frequenc
cfse
cmtmr
cell
specif
lysi
calcul
previous
report
r
cmtmrcell
cfsecel
specificlysi
rcrimm
rc
ratio
pb
control
mice
rimm
ratio
immun
mice
four
week
follow
last
immun
anesthet
mice
challeng
equival
lethal
dose
mouseadapt
influenza
virus
per
nostril
surviv
bodi
weight
clinic
sign
ill
eg
ruffl
fur
hunch
postur
wheez
monitor
daili
week
infect
clinic
score
defin
human
endpoint
anim
meet
criterion
euthan
miivsam
coadministr
studi
mice
infect
whole
mous
lung
collect
hank
balanc
salt
solut
homogen
use
gentl
mac
dissoci
miltenyi
aliquot
collect
centrifug
g
min
suspend
trizol
life
technolog
total
rna
extract
use
phenolchloroform
cdna
gener
use
thermoscript
rtpcr
system
follow
manufactur
instruct
life
technolog
cdna
serv
templat
amplif
influenza
gene
eukaryot
housekeep
gene
realtim
pcr
quantit
rtpcr
perform
triplic
cdna
sampl
use
taqmanunivers
master
mix
ung
appli
biosystem
forward
primer
revers
primer
probe
tttgtgttcacgctcaccgt
tam
use
amplifi
influenza
gene
thermal
cycl
program
follow
initi
min
min
follow
cycl
min
rtpcr
analyz
use
lightcycl
system
roch
viral
titer
calcul
use
compar
ct
method
indic
foldincreas
preinfect
sampl
mrna
express
normal
level
mrna
express
correspond
sampl
assess
viral
titer
cell
recruit
tcell
respons
induc
infect
lung
excis
day
challeng
lung
tissu
complet
dissoci
gentlemax
dissoci
milteni
biotec
previous
describ
briefli
lung
tissu
digest
hank
balanc
salt
solut
life
technolog
contain
calcium
magnesium
presenc
collagenas
mgml
dnase
unitsml
roch
min
homogen
obtain
singlecel
suspens
character
npspecif
cell
recruit
lung
cell
stain
pelabel
pentam
proimmun
min
pb
fetal
bovin
serum
livedead
fixabl
yellow
pe
texa
red
invitrogen
fitc
ic
antigenspecif
cell
perform
previous
describ
sampl
analyz
fac
lsr
ii
special
order
system
bd
bioscienc
use
bd
diva
softwar
bd
bioscienc
anim
studi
carri
complianc
arriv
guidelin
current
italian
legisl
care
use
anim
experiment
legisl
decre
gsk
anim
welfar
polici
standard
protocol
approv
italian
ministri
health
author
novarti
vaccin
anim
welfar
bodi
author
awb
follow
infect
mice
monitor
daili
euthan
exhibit
defin
human
endpoint
preestablish
agreement
gsk
anim
welfar
polici
statist
analys
perform
use
graphpad
prism
softwar
experi
involv
anim
surviv
analyz
mantlecox
logrank
test
statist
analys
mannwhitney
u
test
use
unless
otherwis
indic
p
valu
less
consid
statist
signific
fulllength
np
gene
amplifi
reversetranscrib
rna
genom
influenza
viru
clone
dna
plasmid
backbon
two
monocistron
sam
np
sam
one
bicistron
sam
vector
fig
correspond
ssrna
synthes
vitro
enzymat
transcript
reaction
linear
plasmid
dna
templat
use
rna
polymeras
vitro
activ
monocistron
bicistron
sam
replicon
measur
electropor
bhk
cell
compar
control
selfamplifi
rna
known
potenc
std
presenc
intracellular
dsrna
molecul
marker
rna
amplif
evalu
flow
cytometri
fig
frequenc
dsrna
bhk
cell
transfect
two
sam
np
sam
monocistron
sam
bicistron
replicon
compar
higher
obtain
std
indic
new
replicon
selfamplifi
frequenc
dsrna
protein
cell
compar
replicon
suggest
antigen
express
parallel
rna
amplif
antigen
express
bhk
cell
transfect
differ
sam
replicon
character
western
blot
fig
flow
cytometri
fig
np
protein
express
monocistron
lane
bicistron
lane
vector
show
band
western
blot
molecular
weight
equival
respect
protein
express
virusinfect
bhk
cell
lane
fig
final
percentag
np
express
bhk
cell
greater
monocistron
bicistron
replicon
major
bhk
cell
transfect
bicistron
replicon
coexpress
np
fig
vivo
studi
sam
vector
encapsul
lnp
mean
particl
size
polydispers
measur
dynam
light
scatter
sam
np
lnp
sam
lnp
sam
sam
np
lnp
sam
lnp
zaverag
diamet
rang
nm
low
polydispers
index
data
shown
indic
small
uniform
lipid
particl
abl
encapsul
mrna
final
flow
cytometri
analysi
show
percentag
mfi
bhk
cell
express
np
antigen
transfect
differ
samlnp
formul
compar
singl
antigen
combin
group
fig
assess
immunogen
sam
replicon
express
np
andor
antigen
balbc
mice
immun
im
twice
eight
week
apart
sam
np
sam
mixtur
sam
np
sam
sam
deliv
lnp
infect
low
dose
viru
treatment
pb
use
posit
neg
control
respect
np
igg
alreadi
detect
sera
samimmun
mice
first
dose
boost
second
immun
fig
mice
receiv
singl
antigen
reach
antibodi
titer
fold
higher
p
vaccin
antigen
suggest
np
induc
mild
antigen
interfer
sera
samimmun
mice
fail
neutral
viru
infect
mdck
cell
vitro
fig
consist
intern
locat
antigen
viru
base
key
protect
role
play
np
cell
influenza
diseas
focus
next
set
analys
character
antigenspecif
tcell
ic
flow
cytometri
fig
antigenspecif
cytokinesecret
cell
identifi
among
cell
subset
previous
describ
splenocyt
immun
anim
stimul
vitro
peptid
fig
recombin
np
protein
fig
peptid
pool
fig
npspecif
cell
alreadi
detect
day
first
immun
maintain
frequenc
around
week
fig
increas
seen
day
second
immun
frequenc
npspecif
cell
rang
total
cell
contract
week
major
npspecif
cell
characterist
effector
phenotyp
tcell
detect
mice
sam
vaccin
group
time
point
test
data
shown
similarli
npspecif
cell
alreadi
detect
day
first
immun
predominantli
multifunct
fig
second
immun
expand
npspecif
cell
immun
group
especi
multifunct
subpopul
frequenc
npspecif
cell
rang
week
first
immun
increas
day
second
immun
decreas
week
thereaft
signific
differ
term
intens
qualiti
respons
observ
differ
sam
vaccin
group
except
week
post
time
point
intens
npspecif
cell
respons
significantli
reduc
mice
immun
sam
compar
two
samvaccin
group
tcell
show
kinet
phenotyp
similar
npspecif
cell
albeit
lower
frequenc
fig
differ
observ
frequenc
antigenspecif
tcell
induc
sam
alon
combin
sam
np
mice
preexpos
low
dose
viru
show
approxim
npspecif
cell
respect
increas
second
exposur
viru
like
haspecif
antibodi
induc
first
exposur
neutral
second
viru
infect
thu
prevent
recal
expans
npspecif
tcell
low
frequenc
tcell
respons
cell
detect
infect
mice
observ
sam
immun
mice
np
cell
detect
pbstreat
mice
similar
immun
profil
observ
total
number
rather
frequenc
antigenspecif
cell
report
data
shown
addit
cytokin
secret
character
memori
phenotyp
antigenspecif
cell
spleen
immun
mice
measur
frequenc
effector
teff
effector
memori
tem
central
memori
tcm
cell
differ
time
point
upon
vaccin
fig
low
frequenc
antigenspecif
tcm
tem
teff
cell
measur
first
immun
sam
vaccin
second
immun
frequenc
npspecif
tcm
cell
boost
fig
np
tcm
cell
also
detect
fig
frequenc
tem
teff
increas
second
vaccin
peak
day
contract
week
kinet
observ
major
differ
among
immun
group
except
npspecif
tem
cell
show
significantli
reduc
frequenc
sam
np
sam
sam
vaccin
group
compar
sam
np
immun
mice
altogeth
result
suggest
sam
vaccin
induc
strong
activ
cell
expans
effector
memori
compart
final
character
antigenspecif
cell
induc
sam
vaccin
cytotox
activ
vitro
vivo
fig
cell
cytotox
evalu
quantifi
surfac
express
measur
degranul
process
upon
vitro
antigenstimul
splenocyt
immun
anim
two
immun
sam
np
alon
combin
sam
major
npspecif
cell
fig
immun
sam
np
alon
induc
higher
frequenc
npspecif
cell
compar
combin
vaccin
p
detect
np
cell
suggest
sam
formul
induc
cytotox
cell
evalu
vivo
cytotox
activ
npspecif
cell
equival
number
cfselabel
cmtmrlabel
splenocyt
puls
restrict
peptid
cfse
unrel
peptid
cmtmr
respect
adopt
transfer
mice
immun
sam
np
sam
np
sam
sam
percentag
cfse
cmtmr
cell
present
spleen
measur
flow
cytometri
h
later
fig
specif
lysi
measur
sam
np
immun
mice
specif
lysi
detect
sam
np
sam
sam
immun
group
respect
specif
lysi
detect
pb
treat
mice
confirm
antigenspecif
cytotox
activ
result
demonstr
sam
formul
induc
npspecif
cell
cytotox
activ
vivo
target
cell
puls
immunodomin
np
peptid
furthermor
observ
enhanc
vivo
cytotox
activ
sam
np
vaccin
mice
compar
mice
immun
combin
vaccin
agreement
frequenc
npspecif
cell
observ
vitro
respect
immun
group
fig
explor
protect
efficaci
sam
vaccin
balbc
mice
immun
twice
eight
week
apart
sam
np
sam
sam
sam
np
sam
vector
formul
lnp
challeng
lethal
dose
mouseadapt
homolog
influenza
viru
control
includ
two
group
mice
previous
expos
low
dose
influenza
virus
surviv
weight
loss
clinic
score
measur
day
challeng
fig
mice
immun
sam
replicon
express
np
either
alon
combin
formul
lnp
protect
lethal
infect
homolog
viru
show
substanti
significantli
higher
p
surviv
rate
compar
pbstreat
control
mice
fig
mice
immun
sam
np
sam
np
sam
sam
vaccin
surviv
rate
respect
contrast
administr
sam
vaccin
alon
poorli
protect
surviv
rate
statist
differ
pbstreat
control
mice
surviv
rate
expect
preexpos
mice
complet
protect
homolog
challeng
mice
preexpos
heterosubtyp
viru
partial
protect
surviv
rate
similar
confer
sam
vaccin
transient
bodi
weight
loss
sign
influenza
diseas
observ
immun
group
howev
mice
vaccin
npexpress
replicon
show
rapid
recoveri
diseas
compar
pbstreat
anim
demonstr
significantli
reduc
bodi
weight
loss
fig
clinic
score
fig
inde
day
influenza
infect
anim
immun
sam
np
combin
vaccin
significantli
reduc
lung
viral
titer
compar
pbstreat
mice
p
complet
clear
influenza
viral
particl
lung
day
fig
bodi
weight
loss
clinic
score
indic
intermedi
grade
ill
sam
immun
mice
agreement
surviv
result
slower
control
lung
viral
titer
determin
crossprotect
confer
sam
vaccin
challeng
mice
heterosubtyp
strain
assess
surviv
loss
bodi
weight
overal
clinic
score
sam
vaccin
associ
surviv
reduc
overal
weight
loss
low
clinic
score
fig
contrast
pbstreat
mice
show
poorer
outcom
surviv
rate
bodi
weight
loss
peak
infect
day
clinic
score
differ
protect
efficaci
sam
vaccin
homolog
heterosubtyp
infect
model
could
due
differ
virul
virus
suggest
differ
surviv
rate
observ
pbstreat
mice
vaccin
might
influenc
tcell
respons
influenza
infect
site
viru
entri
therefor
character
lung
tcell
composit
day
challeng
sam
np
sam
sam
np
sam
sam
vaccin
mice
fig
time
influenza
challeng
day
pentam
cell
alreadi
detect
lung
mice
immun
sam
np
combin
sam
pb
number
increas
immun
group
day
infect
remain
high
day
sam
np
combin
group
fig
npspecif
cell
detect
sam
np
combin
group
alreadi
day
frequenc
increas
day
infect
show
complex
phenotyp
day
final
cell
detect
day
sam
vaccin
group
combin
formul
group
fig
agreement
effector
phenotyp
observ
ic
npspecif
cell
found
lung
npimmun
anim
fig
sinc
antigenspecif
cell
also
role
mediat
protect
contribut
develop
effector
function
cell
character
lung
np
cell
vaccin
subsequ
influenza
infect
characterist
profil
observ
system
immun
fig
maintain
infect
lunginfiltr
antigenspecif
cell
express
alon
combin
fig
final
histolog
analysi
lung
vaccin
mice
show
high
number
effector
cell
present
day
onward
challeng
induc
overt
patholog
rather
associ
low
histopatholog
score
fig
altogeth
data
suggest
vaccin
influenc
tcell
respons
lung
influenza
challeng
mice
immun
sam
np
vaccin
show
rapid
enhanc
recruit
cytotox
cell
polyfunct
cell
lung
associ
effici
control
viru
reduc
lung
lesion
significantli
enhanc
surviv
rate
ideal
crossprotect
influenza
vaccin
induc
humor
respons
versu
surfac
ha
antigen
tcell
respons
intern
conserv
influenza
antigen
np
therefor
evalu
possibl
use
rnabas
sam
vaccin
combin
monoval
inactiv
influenza
vaccin
miiv
deriv
viru
balbc
mice
immun
im
twice
eight
week
apart
sam
sam
gfp
control
vector
lnp
combin
suboptim
dose
miiv
chosen
assess
possibl
synergi
sam
vaccin
pbstreat
mice
preexpos
low
dose
influenza
viru
use
neg
posit
control
respect
one
month
last
immun
mice
infect
lethal
dose
viru
increas
stringenc
model
monitor
day
infect
sam
miivimmun
mice
show
surviv
rate
significantli
increas
compar
pb
treat
mice
respect
miiv
alon
provid
partial
protect
experiment
condit
surviv
fig
immun
anim
show
sign
diseas
cours
observ
transient
weight
loss
peak
four
day
infect
fig
surpris
anim
sam
gfp
miiv
vector
control
group
surviv
infect
although
previous
show
sam
gfp
alon
induc
immun
respons
protect
mice
challeng
viru
investig
possibl
adjuv
effect
ssrna
vector
vivo
compar
adapt
immun
respons
induc
differ
vaccin
combin
measur
antigenspecif
function
antibodi
titer
fig
tcell
frequenc
fig
two
week
second
immun
viru
neutral
titer
vaccin
strain
rang
significantli
differ
sera
mice
immun
sam
miiv
sam
gfp
miiv
miiv
alon
neutral
activ
found
viru
fig
confirm
previou
observ
contrast
combin
sam
sam
gfp
miiv
result
increas
frequenc
vaccinespecif
crossreact
cell
compar
miiv
fig
cell
show
polyfunct
effector
phenotyp
consist
combin
moreov
coadministr
sam
replicon
miiv
shift
usual
phenotyp
elicit
miiv
character
product
profil
domin
product
similar
helper
pattern
observ
combin
sam
vector
encod
gfp
antigen
miiv
suggest
polar
tcell
respons
due
replicon
per
se
like
antigendepend
final
np
tcell
respons
normal
observ
mice
immun
sam
miiv
fig
result
demonstr
coadministr
sam
miiv
induc
broader
immun
result
enhanc
protect
heterolog
influenza
virus
compar
miiv
alon
also
first
evid
combin
ssrna
vector
proteinbas
vaccin
might
feasibl
improv
efficaci
current
season
pandem
influenza
vaccin
evid
human
tcell
respons
induc
natur
exposur
influenza
viru
direct
toward
intern
conserv
antigen
np
provid
crossprotect
limit
sever
diseas
studi
assess
immunogen
efficaci
selfamplifi
mrna
vector
encod
np
antigen
separ
combin
formul
synthet
lipid
nanoparticl
sam
vaccin
immunogen
balbc
mice
induc
npspecif
cytotox
cell
cell
cell
sam
vaccin
induc
antigenspecif
tem
tcm
cell
subset
import
longlast
protect
confirm
previou
observ
obtain
rna
vaccin
mice
immun
sam
vaccin
express
np
alon
combin
protect
homolog
heterosubtyp
influenza
challeng
npspecif
cell
infiltr
lung
mice
show
characterist
cytotox
effector
cell
correl
decreas
lung
viral
titer
lower
immunopatholog
score
final
demonstr
coformul
ssrna
sam
vaccin
miiv
subunit
protein
brought
benefit
platform
cell
haspecif
function
antibodi
shift
polar
haspecif
cell
phenotyp
elicit
haspecif
cytotox
cell
increas
protect
heterolog
viru
present
studi
extend
previou
knowledg
immunogen
protect
efficaci
plasmid
dna
dsdna
viral
vector
encod
np
antigen
ssrna
sam
vector
show
immun
respons
direct
toward
np
essenti
protect
mice
homolog
viru
confirm
previou
observ
sinc
mice
immun
sam
np
alon
combin
show
compar
surviv
rate
contrast
mice
immun
sam
show
tcell
respons
limit
subset
agreement
recent
observ
obtain
dna
recombin
vaccinia
viru
vaccin
express
protect
furthermor
sam
vaccin
provid
complet
protect
heterosubtyp
viru
suggest
crossreact
tcell
induc
vaccin
due
high
amino
acid
homolog
np
antigen
virus
seem
essenti
mous
model
influenza
sever
line
evid
human
demonstr
cell
abil
provid
crossprotect
cell
play
crucial
role
viru
clearanc
howev
cytotox
respons
mice
human
usual
focus
fraction
immunogen
epitop
elicit
either
immunodomin
subdomin
respons
influenza
virusinfect
mice
tcell
respons
domin
immunedomin
cytotox
cell
well
establish
individu
support
approach
includ
univers
influenza
vaccin
broad
crossprotect
immun
clinic
studi
use
modifi
vaccinia
viru
ankara
mva
vector
encod
np
conduct
provid
first
evid
safeti
clinic
efficaci
tcellbas
influenza
vaccin
consid
correl
preclin
clinic
data
obtain
vaccin
confid
sam
repres
altern
approach
univers
influenza
vaccin
worth
test
human
ideal
univers
influenza
vaccin
induc
neutral
antibodi
toward
surfaceexpos
antigen
ha
na
reduc
host
cell
infect
well
cell
conserv
intern
antigen
elimin
influenzainfect
cell
provid
broader
protect
case
ha
missmatch
vaccin
circul
strain
test
approach
combin
lead
candid
sam
miiv
demonstr
vaccin
regimen
induc
function
antibodi
respons
ha
tcell
respons
np
antigen
observ
line
report
coadministr
trival
inactiv
influenza
vaccin
preclin
clinic
studi
recent
demonstr
cell
cytotox
cell
also
play
role
protect
heterolog
influenza
strain
interestingli
coadministr
ssrna
sam
regardless
antigen
encod
vector
gfp
act
adjuv
subunit
miiv
vaccin
elicit
effector
cell
increas
magnitud
cell
shift
polar
toward
phenotyp
unclear
adjuv
effect
specif
ssrna
sam
vector
share
dsdna
vector
like
mva
combin
season
vaccin
mva
vector
express
unrel
antigen
report
case
immunemodulatori
effect
rna
engag
toll
nodlik
receptor
wide
describ
literatur
see
review
consid
efficaci
sam
ha
sam
vaccin
mice
vector
might
combin
uniqu
vaccin
abl
induc
cell
b
cellmedi
immun
futur
studi
need
address
immunogen
efficaci
combin
studi
offer
altern
vaccin
platform
technolog
base
ssrna
viral
vector
deliv
conserv
influenza
antigen
induc
protect
immun
respons
similar
nucleic
acidbas
vaccin
mrna
plasmid
dna
dsdna
viral
vector
howev
sam
technolog
combin
posit
immunolog
attribut
dna
viral
vectorbas
vaccin
potenti
overcom
mani
limit
exampl
product
sam
vaccin
requir
biolog
system
cellfre
rapid
highli
scalabl
facilit
rapid
respons
emerg
pathogen
day
need
synthes
prototyp
sam
vaccin
emerg
respons
outbreak
china
cellbas
product
mva
vaccin
took
week
second
low
dose
sam
vaccin
elicit
potent
humor
tcell
respons
small
anim
well
nonhuman
primat
without
risk
genom
integr
antivector
immun
vaccin
platform
base
technolog
induc
broad
spectrum
immun
respons
addit
meet
product
requir
might
benefici
develop
broadspectrum
univers
influenza
vaccin
